A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

  • Cancer
  • Skin Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Albi
  • Antony
  • Bayonne
  • Besançon
  • Bobigny
  • Bourg-en-Bresse
  • Chambéry
  • Clermont-Ferrand
  • Colmar
  • Dijon
  • Le Mans
  • Lille
  • Limoges
  • Marseille
  • Montivilliers
  • Montpellier
  • Mulhouse
  • Nice
  • Paris
  • Poissy
  • Rennes
  • Rouen
  • Saint-Malo
  • Saint-Priest-en-Jarez
  • Strasbourg
  • Thionville
  • Toulon
  • Toulouse
  • Valence
  • Villejuif
  • Épagny-Metz-Tessy
Trial Identifier:

NCT03139513 ML29964

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a multicentre, ambispective (both retrospective and prospective), and non-interventional study conducted in France in adult participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib (Zelboraf®).

      Hoffmann-La Roche Sponsor
      NCT03139513,ML29964 Trial Identifier
      Cobimetinib, Vemurafenib Treatments
      Melanoma Condition
      Official Title

      Survival in Adult Patients With BRAF V600 Mutation-Positive Advanced Melanoma: A Non-Interventional Ambispective Study of a Cohort of Patients Treated With Cobimetinib During the French Early Access Program (TAU)

      Eligibility criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants included in the TAU from 26 February 2015
      • Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib
      • For alive participants: participants who have been informed verbally and in writing about this study who do not object to their data being electronically processed or subjected to data quality control
      • For participants who died before the inclusion period: participants who did not express their opposition when they were alive
      Exclusion Criteria
      • Alive participants unable to give informed consent

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now